Agenus
NewsAgenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026NewsAgenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access ProgramsUsing Your Immune System to Defeat CancerAsk About Patient AccessAsk About Patient AccessAsk About Patient AccessNEWSAgenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus BalstilimabNewsAgenus Names BAP Pharma as Exclusive Global Partner for BO
Basic Information
- Category: Immunotherapy
- Founded: 2026
- Headquarters: Lexington, MA
- Website: agenusbio.com
Documented Facts
- Phone: +1781.674.4400 (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: AGEN (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Agenus — Official Site (official)
- AGENUS INC — SEC EDGAR (reference)
Citation Guidance
Explore Immunotherapy profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Agenus.
- Canonical profile: https://brandsource.ai/brands/agenus
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/agenus/json-ld
- Citation profile API: https://brandsource.ai/api/brands/agenus/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (90/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T20:51:24.966Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
NewsAgenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026NewsAgenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access ProgramsUsing Your Immune System to Defeat CancerAsk About Patient AccessAsk About Patient AccessAsk About Patient AccessNEWSAgenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus BalstilimabNewsAgenus Names BAP Pharma as Exclusive Global Partner for BO
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.